![](/img/cover-not-exists.png)
810PAbiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
Ohlmann, C, Roger, Z, Rüssel, C, Hellmis, E, Suttmann, H, Janssen, M, Hübner, A, Dahm, J, Gleißner, J, Scheffler, M, Feyerabend, S, Telle, J, Klier, JVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy284.019
Date:
October, 2018
File:
PDF, 81 KB
english, 2018